Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

33 questions · 34 findings · 17 reviews · Headline outcomes only

No studies found 3 · 8.8%GRADE not reported 3 · 8.8%Very low 14 · 41.2%Low 8 · 23.5%Moderate 4 · 11.8%High 2 · 5.9%

Intervention not reported

Total number of adverse events · adults with renal vasculitis

The intervention showed no clear difference in total number of adverse events (low certainty).

1 finding from 1 review

Sulfasalazine vs placebo

Withdrawals due to adverse events · Patients with ankylosing spondylitis

Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Paracetamol vs placebo

Total adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip

Paracetamol showed no clear difference in total adverse events: number experiencing 24 weeks compared with placebo (high certainty).

1 finding from 1 review

Diacerein vs placebo

Total number of serious adverse events not measured · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Muscle relaxant vs control

Total Number of Adverse Events ‐ single dose studies · patients with pain management in rheumatoid arthritis

It is very uncertain whether muscle relaxant changes total Number of Adverse Events ‐ single dose studies compared with control (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

Low‐dose colchicine vs NSAIDs

Number of participants reporting an adverse event · acute gout

Low‐dose colchicine showed no clear difference in total number of participants reporting adverse events compared with NSAIDs (low certainty).

1 finding from 1 review

Minimally invasive parathyroidectomy vs bilateral neck exploration

Adverse effects: perioperative complications (number of events)

Minimally invasive parathyroidectomy may leads to lower total incidence of perioperative adverse events (number) compared with bilateral neck exploration (low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).

1 finding from 1 review